Mechanisms by which IGF-I May Promote Cancer (original) (raw)

1. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986:2503–12. [PMC free article] [PubMed] [Google Scholar]

2. Ludwig T, Eggenschweiler J, Fisher P, D’ercole AJ, Davenport ML, Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol. 1996;77:517–35. [PubMed] [Google Scholar]

3. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 1993;290:419–26. [PMC free article] [PubMed] [Google Scholar]

4. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Eidence for a second mechanism of IGF-I signaling. Clin Cancer Res. 1999;5:1935–44. [PubMed] [Google Scholar]

5. Hwa V, Oh Y, Rosenfeld RG. The IGFBP superfamily. Endocr Rev. 1999;20:761–87. [PubMed] [Google Scholar]

6. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther. 2002;1:226–31. [PubMed] [Google Scholar]

7. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997;272:31163–31171. [PubMed] [Google Scholar]

8. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Develop. 1999;13:2905–27. [PubMed] [Google Scholar]

9. Kaffer CR, Grinberg A, Pfeifer K. Regulatory mechanisms at the mouse Igf2/H19 locus. Molec Cell Biol. 2001;21:8189–96. [PMC free article] [PubMed] [Google Scholar]

10. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 2001;98:591–6. [PMC free article] [PubMed] [Google Scholar]

11. DiGiovanni J, Bol DK, Wilker E, Beltran L, Carbajal S, Moats S, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res. 2000;60:1561–70. [PubMed] [Google Scholar]

12. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA. 2000;97:3455–60. [PMC free article] [PubMed] [Google Scholar]

13. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, et al. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Molec Morphol. 2000;8:110–9. [PubMed] [Google Scholar]

14. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1998;83:1713–20. [PubMed] [Google Scholar]

15. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, et al. The IGF system in thyroid cancer: New concepts. Molec Pathol. 2001;54:121–4. [PMC free article] [PubMed] [Google Scholar]

16. Grimberg A, Rajah R, Zhao H, Cohen P. The prostatic IGF System: New levels of complexity. In: Takano K, Hizuka N, Takahashi SI, editors. Molecular Mechanisms to Regulate the Activities of Insulin-Like Growth Factors. Amsterdam: Elsevier Science BV; 1998. pp. 205–13. [Google Scholar]

17. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992;75:1046–53. [PubMed] [Google Scholar]

18. Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lonning PE. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Brit J Cancer. 2001;85:74–7. [PMC free article] [PubMed] [Google Scholar]

19. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205–11. [PubMed] [Google Scholar]

20. Bustin SA, Dorudi S, Phillips SM, Feakins RM, Jenkins PJ. Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol. 2002;23:130–8. [PubMed] [Google Scholar]

21. Tang Y, Zhang D, Fallavollita L, Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003;63:1166–71. [PubMed] [Google Scholar]

22. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab. 2003;88:5392–8. [PubMed] [Google Scholar]

23. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 2002;182:1377–89. [PubMed] [Google Scholar]

24. Clemmons DR, Maile LA. Minireview: Integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinol. 2003;144:1664–70. [PubMed] [Google Scholar]

26. Guvakova MA, Adams JC, Boettiger D. Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci. 2002;115:4149–65. [PubMed] [Google Scholar]

27. Wang F, Duan R, Chirgwin J, Safe SH. Transcriptional activation of cathepsin D gene expression by growth factors. J Molec Endocrinol. 2000;24:193–202. [PubMed] [Google Scholar]

28. Yoon A, Hurta RA. Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Molec Cell Biochem. 2001;223:1–6. [PubMed] [Google Scholar]

29. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene. 2003;22:974–82. [PubMed] [Google Scholar]

30. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plas-minogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase. Cancer Res. 2001;61:1367–74. [PubMed] [Google Scholar]

31. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem. 2001;276:33608–15. [PubMed] [Google Scholar]

32. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90:11217–21. [PMC free article] [PubMed] [Google Scholar]

33. Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, Sitzmann JV, et al. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellu-lar carcinoma. Hepatol. 2002;36:1089–97. [PubMed] [Google Scholar]

34. Oksenberg D, Dieckmann BS, Greenberg PL. Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells. Cancer Res. 1990;50:6471–7. [PubMed] [Google Scholar]

35. Werner H, Shen-Orr Z, Rauscher FJ, 3rd, Morris JF, Roberts CT, Jr, LeRoith D. Inhibition of cellular proliferation by the Wilms’ tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Molec Cell Biol. 1995;15:3516–22. [PMC free article] [PubMed] [Google Scholar]

36. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA. 1996;93:8318–23. [PMC free article] [PubMed] [Google Scholar]

37. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, et al. Regulation of insulin-like growth factor II P3 promotor by p53: A potential mechanism for tumorigene-sis. Cancer Res. 1996;56:1367–73. [PubMed] [Google Scholar]

38. Buckbinder L, Talbott R, VelascoMiguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995;377:646–9. [PubMed] [Google Scholar]

39. van Golen CM, Schwab TS, Ignatoski KM, Ethier SP, Feldman EL. PTEN/MMAC1 over-expression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell Growth Differen. 2001;12:371–8. [PubMed] [Google Scholar]

40. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002;21:5289–300. [PubMed] [Google Scholar]

41. Kim W, Kaelin WG., Jr The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr Opin Genet Dev. 2003;13:55–60. [PubMed] [Google Scholar]

42. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem. 2000;275:20700–6. [PubMed] [Google Scholar]

43. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncol. 2002;63:317–32. [PubMed] [Google Scholar]

44. Lai A, Sarcevic B, Prall OW, Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1) J Biol Chem. 2001;276:25823–33. [PubMed] [Google Scholar]

45. Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH. Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exptl Cell Res. 2002;273:107–17. [PubMed] [Google Scholar]

46. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem. 2001;276:40080–6. [PubMed] [Google Scholar]

47. Campbell MJ, Woodside JV, Secker-Walker J, Titcomb A, Leathem AJ. IGF status is altered by tamoxifen in patients with breast cancer. Molec Pathol. 2001;54:307–10. [PMC free article] [PubMed] [Google Scholar]

48. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat. 2001;69:21–7. [PubMed] [Google Scholar]

49. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474–8. [PubMed] [Google Scholar]

50. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) Cancer Res. 2001;61:6276–80. [PubMed] [Google Scholar]

51. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 2000;60:3058–64. [PubMed] [Google Scholar]

52. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinol. 2001;142:21–7. [PubMed] [Google Scholar]

53. Grimberg A, Cohen P. The role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1–9. [PMC free article] [PubMed] [Google Scholar]

54. Oh Y, Müller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem. 1993;268:26045–8. [PubMed] [Google Scholar]

55. Ricort JM, Lombet A, Lassarre C, Binoux M. Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Let. 2002;527:293–7. [PubMed] [Google Scholar]

56. Ricort JM, Binoux M. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinol. 2001;142:108–13. [PubMed] [Google Scholar]

57. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000;275:33607–13. [PubMed] [Google Scholar]

58. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275:39174–81. [PubMed] [Google Scholar]

59. Grimberg A. p53 and IGFBP-3: Apoptosis and cancer protection. Molec Genet Metab. 2000;70:85–98. [PubMed] [Google Scholar]

60. Grimberg A, Coleman CM, Burns TF, Himelstein BP, David R, Koch CJ, et al. p53-dependent and p53-independent induction of IGFBP-3 by DNA damage and hypoxia. The 84th Annual Meeting of The Endocrine Society Program and Abstracts; 2002; p. 226. [Google Scholar]

61. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Internatl J Oncol. 2002;21:327–35. [PMC free article] [PubMed] [Google Scholar]

62. Grimberg A, Cohen P. GH and prostate cancer: Guilty by association? J Endocrinol Invest. 1999;22:64–73. [PMC free article] [PubMed] [Google Scholar]

63. Pollak M. Insulin-like growth factor physiology and cancer risk. Europ J Cancer. 2000;36:1224–18. [PubMed] [Google Scholar]

64. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96:7324–9. [PMC free article] [PubMed] [Google Scholar]

65. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62:1030–5. [PubMed] [Google Scholar]

66. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, LeRoith D, et al. Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res. 1998;58:3021–7. [PubMed] [Google Scholar]

67. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarci-noma. Proc Natl Acad Sci USA. 1997;94:5810–3. [PMC free article] [PubMed] [Google Scholar]

68. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Brit J Cancer. 2000;82:1724–31. [PMC free article] [PubMed] [Google Scholar]

69. Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, et al. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate. 2002;52:173–82. [PubMed] [Google Scholar]

70. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, et al. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II. Cancer. 2002;95:1735–45. [PubMed] [Google Scholar]

71. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94:487–92. [PubMed] [Google Scholar]

72. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Brit J Cancer. 2001;85:428–30. [PMC free article] [PubMed] [Google Scholar]

73. Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther. 2003;10:57–63. [PubMed] [Google Scholar]

74. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 2003;63:627–35. [PubMed] [Google Scholar]

75. Scotlandi K, Maini C, Manara MC, Benini S, Serra M, Cerisano V, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing’s sarcoma cells. Cancer Gene Ther. 2002;9:296–307. [PubMed] [Google Scholar]

76. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003;278:15991–7. [PubMed] [Google Scholar]

77. Ly A, Francois JC, Upegui-Gonzalez LC, Swiercz B, Bedel C, Duc HT, et al. Alterations in tumorigenicity of embryonal carcinoma cells by IGF-I triple-helix induced changes in immunogenicity and apoptosis. Life Sci. 2000;68:307–19. [PubMed] [Google Scholar]

78. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997;57:4667–72. [PubMed] [Google Scholar]

79. Hursting SD, Perkins SN, Phang JM, Barrett JC. Diet and cancer prevention studies in p53-deficient mice. J Nutrit. 2001;131:3092S–4S. [PubMed] [Google Scholar]

80. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: International evaluation of the evidence. Eur J Cancer Prevent. 2002;11(S2):S94-100. [PubMed] [Google Scholar]